Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Circulating Tumor DNA Dynamics and Treatment Outcome of Regorafenib in Metastatic Colorectal Cancer.

Cancer research and treatment - 1 Jul 2023

Lee Dae-Won, Lim Yoojoo, Kim Hwang-Phill, Kim Su Yeon, Roh Hanseong, Kang Jun-Kyu, Lee Kyung-Hun, Kim Min Jung, Ryoo Seung-Bum, Park Ji Won, Jeong Seung-Yong, Park Kyu Joo, Kang Gyeong Hoon, Han Sae-Won, Kim Tae-You

Abstract excerpt

PURPOSE: Circulating tumor DNA (ctDNA) is emerging as a valuable non-invasive tool to identify tumor heterogeneity and tumor burden. This study investigated ctDNA dynamics in metastatic colorectal cancer patients treated with regorafenib. Materials and Methods: In this prospective biomarker study, plasma cell-free DNA (cfDNA) samples obtained at baseline, at the first response evaluation after 2 cycles of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Cell-Free Nucleic Acids

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Circulating Tumor DNA

Share to Colonic Neoplasms

Share to Colorectal Neoplasms

Share to Protein-Tyrosine Kinases

Share to Proto-Oncogene Proteins

Share to Rectal Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 36915247
DOI: 10.4143/crt.2023.268
PMCID: PMC10372591

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Circulating Tumor DNA Dynamics and Treatment Outcome of Regorafenib in Metastatic Colorectal Cancer.PMID 36915247Read ↗

Monitoring levels of circulating cell‐free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatmentSemantic proximity Read ↗

A higher ctDNA fraction decreases survival in regorafenib‐treated metastatic colorectal cancer patients. Results from the regorafenib's liquid biopsy translational biomarker phase II pilot studySemantic proximity Read ↗

Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.Semantic proximity Read ↗

Clinical and molecular assessment of regorafenib monotherapy.Semantic proximity Read ↗

Serial profiling of circulating tumor DNA for optimization of anti-VEGF chemotherapy in metastatic colorectal cancer patients.Semantic proximity Read ↗

Mutational evolution after chemotherapy-progression in metastatic colorectal cancer revealed by circulating tumor DNA analysis.Semantic proximity Read ↗

Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer.Semantic proximity Read ↗

Cancer treatment monitoring using cell-free DNA fragmentomes.Semantic proximity Read ↗

Targeted Sequencing of Circulating Tumor DNA to Monitor Genetic Variants and Therapeutic Response in Metastatic Colorectal Cancer.Semantic proximity Read ↗

Circulating tumor DNA sequencing in colorectal cancer patients treated with first-line chemotherapy with anti-EGFRSemantic proximity Read ↗

Clinical utility of longitudinal circulating tumor DNA analysis in metastatic colorectal cancer patients receiving palliative chemotherapy.Semantic proximity Read ↗

Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Colorectal Cancer: Implications for Response and Resistance to Targeted TherapeuticsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.